Yong-June Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1263368/publications.pdf

Version: 2024-02-01

535685 425179 1,273 64 17 34 citations h-index g-index papers 64 64 64 2205 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	1.0	3
2	A high basal metabolic rate is an independent predictor of stone recurrence in obese patients. Investigative and Clinical Urology, 2021, 62, 195.	1.0	4
3	Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma. Investigative and Clinical Urology, 2021, 62, 399.	1.0	2
4	Efficacy and Tolerability of Solifenacin Fumarate with Overactive Bladder Patients: A Multicenter Observational Study. Urogenital Tract Infection, 2021, 16, 8-15.	0.1	0
5	Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study. BMC Urology, 2021, 21, 85.	0.6	1
6	Integrative Transcriptome Profiling Reveals SKA3 as a Novel Prognostic Marker in Non-Muscle Invasive Bladder Cancer. Cancers, 2021, 13, 4673.	1.7	5
7	Nutritional status assessed by the Controlling Nutritional Status (CONUT) score as a predictor of recurrence of urolithiasis. Investigative and Clinical Urology, 2021, 62, 553.	1.0	2
8	The prognostic value of the pretreatment serum albumin to globulin ratio for predicting adverse pathology in patients undergoing radical prostatectomy for prostate cancer. Investigative and Clinical Urology, 2021, 62, 545.	1.0	6
9	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 12756.	1.8	7
10	A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study. Nutrition and Cancer, 2020, 72, 88-97.	0.9	19
11	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	1.2	24
12	Intraoperative allogeneic blood transfusion is associated with adverse oncological outcomes in patients with surgically treated non-metastatic clear cell renal cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 1551-1561.	1.0	4
13	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	1.0	7
14	Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. International Urology and Nephrology, 2019, 51, 1129-1135.	0.6	8
15	The prognostic significance of preexisting diabetes in patients with surgically treated renal cell carcinoma: the ongoing debate. Annals of Translational Medicine, 2019, 7, S321-S321.	0.7	1
16	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array‑based DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	1.2	6
17	Gender―and cholesterolâ€specific predictive value of body mass index in renal cell carcinoma: A multicenter study. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e36-e42.	0.7	2
18	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	1.1	17

#	Article	IF	Citations
19	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	1.0	2
20	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	0.9	8
21	Electrochemical detection of methylated DNA on a microfluidic chip with nanoelectrokinetic pre-concentration. Biosensors and Bioelectronics, 2018, 107, 103-110.	5.3	60
22	Sex-Specific Prognostic Significance of Obesity in Nonmetastatic Clear-Cell Renal-Cell Carcinoma in Korea: A Large Multicenter Cohort Analysis. Clinical Genitourinary Cancer, 2018, 16, e173-e179.	0.9	7
23	Low preoperative serum cholesterol level is associated with aggressive pathologic features and poor cancer-specific survival in patients with surgically treated renal cell carcinoma. International Journal of Clinical Oncology, 2018, 23, 142-150.	1.0	20
24	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	1.1	19
25	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	0.9	18
26	Ageâ€dependent prognostic value of body mass index for nonâ€metastatic clear cell renal cell carcinoma: A large multicenter retrospective analysis. Journal of Surgical Oncology, 2018, 118, 199-205.	0.8	9
27	Metabolic Characteristics and Risks Associated with Stone Recurrence in Korean Young Adult Stone Patients. Journal of Endourology, 2017, 31, 806-811.	1.1	7
28	Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. Journal of Urology, 2017, 198, 1340-1345.	0.2	2
29	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncology Letters, 2017, 14, 2468-2474.	0.8	6
30	Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients. Journal of Korean Medical Science, 2017, 32, 1496.	1.1	7
31	Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Journal of Korean Medical Science, 2017, 32, 335.	1.1	10
32	Impact of preoperative thrombocytosis on prognosis after surgical treatment in pathological T1 and T2 renal cell carcinoma: results of a multi-institutional comprehensive study. Oncotarget, 2017, 8, 64449-64458.	0.8	6
33	The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investigative and Clinical Urology, 2016, 57, 50.	1.0	30
34	A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma. Journal of Korean Medical Science, 2016, 31, 1983.	1.1	3
35	Association between Perioperative Blood Transfusion and Oncologic Outcomes after Curative Surgery for Renal Cell Carcinoma. Journal of Cancer, 2016, 7, 965-972.	1.2	17
36	Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis. BioMed Research International, 2016, 2016, 1-8.	0.9	20

#	Article	IF	CITATIONS
37	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	1.1	20
38	Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal of Korean Medical Science, 2015, 30, 937.	1.1	8
39	Clinical Implications and Prognostic Values of <i>Prostate Cancer Susceptibility Candidate </i> Methylation in Primary Nonmuscle Invasive Bladder Cancer. Disease Markers, 2015, 2015, 1-6.	0.6	8
40	Role of 1,25-Dihydroxy Vitamin D ₃ and Parathyroid Hormone in Urinary Calcium Excretion in Calcium Stone Formers. Yonsei Medical Journal, 2014, 55, 1326.	0.9	13
41	Effect of Renal Insufficiency on Stone Recurrence in Patients with Urolithiasis. Journal of Korean Medical Science, 2014, 29, 1132.	1.1	13
42	Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence. Korean Journal of Urology, 2014, 55, 520.	1.2	3
43	Distinct Metabolic Characteristics and Risk of Stone Recurrence in Patients With Multiple Stones at the First-time Presentation. Urology, 2014, 84, 274-278.	0.5	4
44	The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 458-465.	0.8	9
45	Hypertriglyceridemia Is Associated With Increased Risk for Stone Recurrence in Patients With Urolithiasis. Urology, 2014, 84, 766-771.	0.5	21
46	<i>HOXA9</i> , <i>ISL1</i> and <i>ALDH1A3</i> methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Arrayâ€based DNA methylation and expression profiling. International Journal of Cancer, 2013, 133, 1135-1142.	2.3	100
47	Multi-Institutional Analysis of Localized Renal Cell Carcinoma that Demonstrates the Impact of Diabetic Status on Prognosis After Nephrectomy. Annals of Surgical Oncology, 2013, 20, 3662-3668.	0.7	27
48	Pyrosequencing Analysis of APCM ethylation Level in Human Prostate Tissues: A Molecular Marker for Prostate Cancer. Korean Journal of Urology, 2013, 54, 194.	1.2	6
49	DNA Methylation of <i>GSTP1 </i> i>in Human Prostate Tissues: Pyrosequencing Analysis. Korean Journal of Urology, 2012, 53, 200.	1.2	17
50	Hypertension Influences Recurrent Stone Formation in Nonobese Stone Formers. Urology, 2011, 77, 1059-1063.	0.5	19
51	<i>EFEMP1</i> as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research, 2011, 17, 4523-4530.	3.2	61
52	<i>GSTT1</i> as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer. Disease Markers, 2010, 29, 81-87.	0.6	11
53	Gene Signatures for the Prediction of Response to Bacillus Calmette-Guérin Immunotherapy in Primary pT1 Bladder Cancers. Clinical Cancer Research, 2010, 16, 2131-2137.	3.2	47
54	Expression Signature of <i>E2F1</i> and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors. Journal of Clinical Oncology, 2010, 28, 2660-2667.	0.8	296

#	Article	IF	CITATIONS
55	Can We Use Single Nucleotide Polymorphism and Runt Domain Transcription Factor 3 Methylation as Tumor Markers for Bladder Cancer?. Korean Journal of Urology, 2009, 50, 311.	1.2	1
56	Changes in Urinary Lithogenic Features Over Time in Patients With Urolithiasis. Urology, 2009, 74, 51-55.	0.5	8
57	The Relationship between RUNX3 Inactivation and Its Pathological Features in Renal Cell Carcinoma. Korean Journal of Urology, 2009, 50, 432.	1.2	2
58	The association between metabolic syndrome and prostateâ€specific antigen levels. International Journal of Urology, 2008, 15, 905-909.	0.5	21
59	Methylation of the RUNX3 Promoter as a Potential Prognostic Marker for Bladder Tumor. Journal of Urology, 2008, 180, 1141-1145.	0.2	71
60	Impact of Obesity in Patients With Urolithiasis and its Prognostic Usefulness in Stone Recurrence. Journal of Urology, 2008, 179, 570-574.	0.2	84
61	Comparison of Perioperative Outcomes of Extraperitoneal Laparoscopic Radical Prostatectomy (ELRP) versus Open Radical Retropubic Prostatectomy (RRP): Single Surgeon's Initial Experience. Korean Journal of Urology, 2007, 48, 131.	0.2	6
62	Utility of Smo as a Prognostic Marker for Human Bladder Tumors. Korean Journal of Urology, 2007, 48, 997.	0.2	4
63	Biomarkers in Bladder Cancer: Present Status and Perspectives. Biomarker Insights, 2007, 2, 117727190700200.	1.0	2
64	Body mass index influences prostate $\hat{a} \in \text{specific}$ antigen in men younger than $60\hat{a} \in f$ years of age. International Journal of Urology, 2007, 14, 1009-1012.	0.5	22